Investor Connect

Highlights: ·           The company has announced the closing of the first tranche of its non-brokered private placement of units for gross proceeds of $690K. Each unit contains one common share in the capital of the company and one common share purchase warrant. ·           Hemostemix Inc recently announced that it has incorporated PreCerv Inc. as a wholly owned subsidiary. PreCerv will get the license to use NCP-01 and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system. ·           Hemostemix Inc. has appointed Mr. Peter Pavlin to the position of Vice President Operations for the company.  He was a consultant to Vadeko International, applied state of the art real time tracking technology, evaluating the performance of the NASA Space Shuttle ASRM. Hemostemix Inc (OTC: HMTXF) (TSX-V: HEM) is a Canada based publicly-traded autologous stem cell therapy company. The company has published seven peer reviewed articles about the safety and